Prolonged blockade of CD40-CD40 ligand interactions by gene transfer of CD40Ig results in long-term heart allograft survival and donor-specific hyporesponsiveness, but does not prevent chronic rejection.
Previous work on blockade of CD40-CD40 ligand interaction in mice and primates with anti-CD40 ligand mAbs has resulted in a moderate prolongation of allograft survival without the development of true allograft tolerance. In this study, we show in rats that adenovirus-mediated gene transfer of CD40Ig sequences into the graft resulted in prolonged (>200 days) expression of CD40Ig and in long-term (>300 days) survival. Recipients expressing CD40Ig displayed strongly (>90%) inhibited mixed leukocyte reactions and alloantibody production at early (days 5 and 17) and late time points (>100 day) after transplantation, but showed limited inhibition of leukocyte infiltration and cytokine production as evaluated by immunohistology at early time points (day 5). Recipients of long-surviving hearts showed donor-specific hyporesponsiveness since acceptance of second cardiac allografts was donor specific. Nevertheless, long-term allografts (>100 days) displayed signs of chronic rejection vasculopathy. Occluded vessels showed leukocyte infiltration, mainly composed of CD4(+) and CD8(+) cells, macrophages, and mast cells. These recipients also showed antidonor CTL activity. Recipients expressing CD40Ig did not show nonspecific immunosuppression, as they were able to mount anticognate immune responses that were partially inhibited at early time points and were normal thereafter. We conclude that gene transfer-mediated expression of CD40Ig resulted in a highly efficient inhibition of acute heart allograft rejection in rats. This treatment induced donor-specific inhibition of certain alloreactive mechanisms in the short-, but not the long-term, which resulted in long-term survival of allografts concomitant with the development of chronic rejection.
Guillot
Cécile
C
Institut National de la Santé et de la Recherche Médicale, Institut de Transplantation et Recherche en Transplantation, Nantes, France.
Guillonneau
Carole
C
Mathieu
Patrick
P
Gerdes
Christian A
CA
Ménoret
Séverine
S
Braudeau
Cécile
C
Tesson
Laurent
L
Renaudin
Karine
K
Castro
Maria G
MG
Löwenstein
Pedro R
PR
Anegon
Ignacio
I
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D019013:CD40 Antigens / Q000276:immunology* / Q000378:metabolism*; D023201:CD40 Ligand / Q000378:metabolism*; D002465:Cell Movement; D002478:Cells, Cultured; D005822:Genetic Vectors; D006084:Graft Rejection / Q000276:immunology* / Q000473:pathology; D006085:Graft Survival / Q000276:immunology*; D016027:Heart Transplantation / Q000276:immunology* / Q000473:pathology; D007136:Immunoglobulins / Q000235:genetics / Q000378:metabolism; D007518:Isoantibodies / Q000096:biosynthesis; D007519:Isoantigens / Q000276:immunology; D007700:Kinetics; D007962:Leukocytes / Q000276:immunology; D008213:Lymphocyte Activation; D008297:Male; D051381:Rats; D011917:Rats, Inbred Lew; D013154:Spleen / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014161:Transduction, Genetic
D019013:CD40 Antigens; D007136:Immunoglobulins; D007518:Isoantibodies; D007519:Isoantigens; D023201:CD40 Ligand